Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials.
Hedde D BiesmaTanya T D SoeratramKarolina SikorskaIrene A CaspersHendrik F van EssenJacqueline M P EgthuijsenAart MookhoekHanneke W M van LaarhovenMark I van Berge HenegouwenMarianne NordsmarkDonald L van der PeetFabienne A R M WarmerdamMaud M GeenenOlaf J L LoosveldJohanneke E A PortieljeMaartje LosDaniëlle A M HeidemanElma Meershoek-Klein KranenbargHenk H HartgrinkJohanna van SandickMarcel VerheijCornelis J H van de VeldeAnnemieke CatsBauke YlstraNicole C T van GriekenPublished in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2022)
In resectable GC, MSI-high had favorable outcome compared to EBV-/MSS, both in patients treated with surgery only, and in those treated with perioperative chemo(radio)therapy. Substantial histopathological response was restricted to mucinous MSI-high tumors. The mucinous phenotype might be a relevant parameter in future clinical trials for MSI-high patients.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- clinical trial
- newly diagnosed
- rectal cancer
- low grade
- end stage renal disease
- ejection fraction
- minimally invasive
- squamous cell carcinoma
- epstein barr virus
- stem cells
- randomized controlled trial
- sentinel lymph node
- diffuse large b cell lymphoma
- atrial fibrillation
- mass spectrometry
- current status
- acute coronary syndrome
- bone marrow
- mesenchymal stem cells
- surgical site infection
- open label
- gas chromatography
- combination therapy
- drug delivery
- phase ii
- patient reported
- percutaneous coronary intervention
- smoking cessation